Prof. Dr Vulsteke Christof

Christof Vulsteke graduated with his Doctor of Medicine degree from Catholic University of Leuven in 2007. He then started his specialist training in internal diseases, with a sub-specialisation in 2010 in medical oncology at Leuven University Hospital, Gasthuisberg campus. He received the highest academic degree (PhD) from the Antwerp Doctoral School (University of Antwerp), with a thesis entitled ‘The impact of genetic variability on chemotherapy-induced toxicity and outcome in early breast cancer patients’. Christof Vulsteke has been the principal investigator of more than 60 international studies and has published more than 70 articles in international journals (including the New England Journal of Medicine, The Lancet Oncology and The Journal of Clinical Oncology). He developed particular national and international expertise in the treatment of urogenital and gynaecologic tumours.

Prof. Christof Vulsteke, MD, is the coordinator for the Integrated Cancer Centre in Ghent (ICG) and is the head of the Clinical Research Department for Medical Oncology. He is an affiliated guest professor at the University of Antwerp (Centre for Oncology Research).

Publications: You may find the complete list on the Web of Science (https://publons.com/researcher...).

Additional certification

• Doctorate in Medical Sciences (PhD)
• People Manager (Vlerick Business School)

Additional responsibilities

• Coordinator for Integrated Cancer Centre in Ghent (IKG)
• Head of the Clinical Research Department for Medical Oncology
• Visiting Professor at the University of Antwerp, Centre for Oncological Research (CORE), Integrated Personalised and Precision Oncology Network (IPPON)
• Chair of the Multidisciplinary Committee for Oncology (MCO) Maria Middelares General Hospital Medical Centre - St Vincent General Hospital in Deinze

Research activities

Awards and achievements

• Award for ‘Best Clinical Article 2013’, Fund for the Promotion of Internal Medicine, Prof. Dr W. Peetermans (Chair)
• Award for the best scientific presentation at the annual BSMO symposium on 11 February 2012, Brussels
• Merit Award 2012 from the American Society of Clinical Oncology, Chicago, Illinois
• Press release: EBCC-8: ‘Understanding individual genetic variation can help predict chemotherapy side effects’.

Peer review

• Member of The Lancet Peer Review Team

Memberships

• Belgian Society of Medical Oncology (BSMO)
• Breast Cancer Task Force (BSMO)
• Prostate Cancer Task Force (BSMO)
• Renal Cancer Task Force (BSMO)
• American Society of Clinical Oncology (ASCO)
• Belgian Gynaecological Oncology Group (BGOG)
• European Organisation for Research and Treatment of Cancers (EORTC)
• Gynaecological Cancers Group (EORTC)
• Breast Cancer Group (EORTC)
• Genito-Urinary Cancers Group (EORTC)
• Melanoma Group (EORTC)
• Impact of Neurotropenia in Chemotherapy – European Study Group (INC-EU)